BioMark Diagnostics Inc
CNSX:BUX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its Industry Average (6.4), the stock would be worth CA$-0.09 (114% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -44.4 | CA$0.6 |
0%
|
| Industry Average | 6.4 | CA$-0.09 |
-114%
|
| Country Average | 10.9 | CA$-0.15 |
-125%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
B
|
BioMark Diagnostics Inc
CNSX:BUX
|
63.1m CAD | -44.4 | -37.1 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
308.8B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | 45 422.5 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
101.6B ZAR | 11.4 | 10.5 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
68.1B USD | -45 994.5 | 38 458.7 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
55.3B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
38.1B CHF | 0 | 0 | |
| US |
|
Coupang Inc
F:788
|
32.4B EUR | 20.5 | 174.4 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
35.8B USD | 41.2 | -3 234.2 | |
| US |
Q
|
Qnity Electronics Inc
NYSE:Q
|
30.3B USD | 0 | 0 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 7.2 |
| Median | 10.9 |
| 70th Percentile | 17 |
| Max | 26 053.9 |
Other Multiples
BioMark Diagnostics Inc
Glance View
BioMark Diagnostics, Inc. engages in development and commercialization of cancer diagnostic solutions to detect, monitor, and assess treatment for cancer. The company is headquartered in Richmond, British Columbia. The company went IPO on 2014-11-03. The Company’s cancer diagnostic solutions can help detect, monitor and assess treatment for cancer. Its cancer diagnostics technology platform leverages Omics and machine learning, which allows for early cancer detection. The firm is focused on bringing its cancer diagnostic kits and detection solution to commercialization standards. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. The firm has developed a liquid biopsy metabolic panel assay. This metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections. The capabilities include early stage I and II Lung Cancers using urine and plasma.
